Evidence map›Paper›PMID 35668702›Full record

Observational studyThe Journal of infectious diseases2022

Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings.

Joanne M Langley, Veronique Bianco, Joseph B Domachowske, Shabir A Madhi, Sonia K Stoszek, Khalequ Zaman, Agustin Bueso, Ana Ceballos, Luis Cousin, Ulises D'Andrea and 16 more

Registry-linked trialOpen access · hybridAbstract readObservational Study
In one paragraph

Observational study in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01995175 (A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01995175 nacompletednot on this map

A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years

TypeinterventionalSponsorGlaxoSmithKlineRan2013 to 2021Enrolled2,409ConditionsRespiratory Syncytial VirusArmsNasal swab sampling, Blood sampling, Diary cards
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Gingipain proteases from the bacteriumProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Journal of preventive medicine and hygiene · 2024
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 10 countries.

Joanne M LangleyCanadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Nova Scotia, Canada.
Veronique BiancoGSK, Rockville, Maryland, USA.
Joseph B DomachowskeDepartment of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.
Shabir A MadhiSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Sonia K StoszekGSK, Rockville, Maryland, USA.
Khalequ ZamanInternational Centre for Diarrheal Disease, Dhaka, Bangladesh.
Agustin BuesoDEMEDICA, San Pedro Sula, Honduras.
Ana CeballosInstituto Medico Rio Cuarto, Rio Cuarto, Cordoba, Argentina.
Luis CousinTecnologia en Investigacion, San Pedro Sula, Honduras.
Ulises D'AndreaInstituto Medico Rio Cuarto, Rio Cuarto, Cordoba, Argentina.
Ilse DieussaertGSK, Rockville, Maryland, USA.
Janet A EnglundSeattle Children's Research Institute, University of Washington, Seattle, Washington, USA.
Sanjay GandhiGSK, Mumbai, India.
Olivier GruselleGSK, Wavre, Belgium.
Gerco HaarsGSK, Wavre, Belgium.
Lisa JoseSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Nicola P KleinKaiser Permanente Vaccine Study Center, Oakland, California, USA.
Amanda LeachGSK, Rockville, Maryland, USA.
Koen MaleuxGSK, Wavre, Belgium.
Thi Lien Anh NguyenGSK, Wavre, Belgium.
Thanyawee PuthanakitThe Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Peter SilasWee Care Pediatrics, Syracuse, Utah, USA.
Auchara TangsathapornpongFaculty of Medicine, Thammasat University, Pathum Thani, Thailand.
Jamaree TeeratakulpisarnFaculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Timo VesikariVaccine Research Center, University of Tampere, Tampere, Finland.
Rachel A CohenGSK, Rockville, Maryland, USA.
GlaxoSmithKline (United States) · USGlaxoSmithKline (Belgium) · BEHonduras Foundation for Agricultural Research · HNInstituto Médico Río Cuarto · ARSouth African Medical Research Council · ZAChulalongkorn University · THGlaxoSmithKline (India) · INInternational Centre for Diarrhoeal Disease Research · BDKaiser Permanente · USKhon Kaen University · THNova Scotia Health Authority · CASeattle Children's Hospital · USSUNY Upstate Medical University · USTampere University · FIThammasat University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe true burden of lower respiratory tract infections (LRTIs) due to respiratory syncytial virus (RSV) remains unclear. This study aimed to provide more robust, multinational data on RSV-LRTI incidence and burden in the first 2 years of life.

methodsThis prospective, observational cohort study was conducted in Argentina, Bangladesh, Canada, Finland, Honduras, South Africa, Thailand, and United States. Children were followed for 24 months from birth. Suspected LRTIs were detected via active (through regular contacts) and passive surveillance. RSV and other viruses were detected from nasopharyngeal swabs using PCR-based methods.

resultsOf 2401 children, 206 (8.6%) had 227 episodes of RSV-LRTI. Incidence rates (IRs) of first episode of RSV-LRTI were 7.35 (95% confidence interval [CI], 5.88-9.08), 5.50 (95% CI, 4.21-7.07), and 2.87 (95% CI, 2.18-3.70) cases/100 person-years in children aged 0-5, 6-11, and 12-23 months. IRs for RSV-LRTI, severe RSV-LRTI, and RSV hospitalization tended to be higher among 0-5 month olds and in lower-income settings. RSV was detected for 40% of LRTIs in 0-2 month olds and for approximately 20% of LRTIs in older children. Other viruses were codetected in 29.2% of RSV-positive nasopharyngeal swabs.

conclusionsA substantial burden of RSV-LRTI was observed across diverse settings, impacting the youngest infants the most. Clinical Trials Registration. NCT01995175.

Indexed as

Respiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsVirusesChildHospitalizationHumansIncidenceInfantProspective Studiesburden of diseaseepidemiologyincidenceinfantsrespiratory syncytial virusrespiratory tract infectionsyoung children

Identifiers

PMID35668702
PMCPMC9417131
OpenAlexW4282044885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.